In one recent study, C. minuta has been confirmed to produce a novel class of secondary bile acid, 3-O-acylcholic acids, which targets and inhibits the farnesoid X receptor (FXR) in the gut, thereby modulating the enterohepatic axis and significantly ameliorating metabolic disorders in model mice (21). Here, NR1H4 is linked to metabolic disease.